EBC-46

Intratumoral Drug Approvals: The Unique Regulatory Challenges Facing EBC-46

Intratumoral drugs like tigilanol tiglate must satisfy regulatory requirements that conventional systemic cancer therapies were never designed to address — from injection site assessment to lesion-level endpoints.

Marcus Webb

Marcus Webb

— 2 min read
Scales of justice in a modern government building symbolising regulatory oversight

Why Intratumoral Drugs Face a Different Regulatory Landscape

Most oncology drugs are systemic — they circulate through the bloodstream and affect the entire body. Tigilanol tiglate (EBC-46) belongs to a fundamentally different class: intratumoral agents, injected directly into a tumour mass.[1] This distinction creates regulatory challenges that the standard approval framework was not originally designed to handle.

The FDA and EMA have historically evaluated cancer drugs through endpoints like overall survival, progression-free survival, and objective response rates measured across the whole body. Intratumoral therapies, however, produce localised effects — rapid necrosis and immune activation at the injection site — that do not fit neatly into these established measurement frameworks.[2]

Injection Site Assessment: A New Endpoint Category

When the FDA approved Stelfonta (tigilanol tiglate) for veterinary use in 2020, it relied on injection site response rates — the proportion of treated tumours that achieved complete resolution after direct injection.[3] This endpoint had no direct precedent in human oncology drug approvals.

For human trials, regulators must decide whether injection site complete response is sufficient as a primary endpoint or whether systemic evidence of immune activation, measured through circulating biomarkers and distant lesion monitoring, must also be demonstrated. This question sits at the intersection of local therapy and immunology.

The Tumour Accessibility Question

Unlike a pill or infusion, an intratumoral drug requires physical access to the tumour. Regulatory agencies must evaluate which tumour types, locations, and sizes are appropriate for injection-based treatment.[4] Subcutaneous and cutaneous lesions are the most accessible, but deeper visceral tumours present technical challenges that could limit the approved indication.

Trial protocols for tigilanol tiglate have therefore focused on accessible solid tumours — head and neck squamous cell carcinoma, melanoma, and soft tissue sarcoma — where ultrasound-guided or direct injection is feasible.[5]

Combination Therapy Complicates the Pathway

There is growing scientific interest in combining EBC-46 with checkpoint inhibitors, leveraging the immune cascade triggered by PKC activation to prime the tumour microenvironment for systemic immunotherapy.[6] However, combination drug approvals require each component to demonstrate independent contribution to efficacy — a high evidentiary bar that demands carefully designed factorial or sequential trial designs.

Accelerated Pathways: Orphan Drug and Breakthrough Therapy

QBiotics has secured Orphan Drug Designation for tigilanol tiglate in specific rare tumour types, which provides regulatory incentives including reduced fees, extended exclusivity, and FDA guidance support.[7] Breakthrough Therapy Designation, if granted, would add intensive FDA guidance and rolling review — both of which could significantly compress the approval timeline.

The EMA's PRIME (Priority Medicines) designation offers a parallel accelerated pathway in Europe, with early scientific dialogue and accelerated assessment once a marketing application is submitted.[8]

What This Means for Patients

The regulatory pathway for intratumoral drugs is being written in real time, partly through the precedent that Stelfonta has already set in veterinary medicine. Every milestone that tigilanol tiglate achieves in human trials helps define how future intratumoral agents will be evaluated. For patients with accessible solid tumours who have exhausted standard options, this regulatory evolution is not abstract — it directly determines when and how they might access a novel treatment.

References

  1. Boyle GM et al. (2014) Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PubMed ↗
  2. FDA approves Stelfonta for canine mast cell tumors (2020). FDA.gov ↗
  3. FDA Stelfonta veterinary approval — injection site endpoints. FDA.gov ↗
  4. Active tigilanol tiglate clinical trials on ClinicalTrials.gov. ClinicalTrials.gov ↗
  5. Panizza BJ et al. (2019) Phase I dose-escalation study of tigilanol tiglate in patients with solid tumours. PubMed ↗
  6. Newton AC (2018) Protein kinase C: perfectly balanced. Critical Reviews in Biochemistry and Molecular Biology. PubMed ↗
  7. FDA Orphan Drug Designation programme overview. FDA.gov ↗
  8. EMA Stelfonta veterinary EPAR — European regulatory pathway. EMA ↗

Read more